Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma

Join Gregory Daniels, MD, PhD and Brian Hinds, MD from the University of California, San Diego as they present their expertise on a range of cases pertaining to melanoma.

It was estimated that in 2015, 73,870 patients in the United States would be diagnosed with melanoma and about 9940 would die from the disease. The incidence of melanoma continues to increase dramatically, at an overall rate of 33% for men and 23% women from 2002 to 2006. On average, an individual loses 20.4 years of potential life as a result of melanoma mortality compared to 16.6 years for all malignancies. The landscape of treatment options for advanced melanoma is both particularly complex and rapidly shifting. Recently published results from large randomized trials in advanced melanoma support FDA approvals and changes in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Melanoma that significantly increase the number of recommended treatment options for phase III and phase IV disease. New recommended treatment options include (1) biochemotherapy and high-dose ipilimumab for select patients with Stage III disease rendered free of disease by surgery; (2) intralesional injection with talimogene laherparepvec for primary treatment of stage III in-transit disease and select lesions in patients with stage IV disease; and (3) two combination therapy regimens for metastatic or unresectable disease: nivolumab/ipilimumab and vemurafenib/cobimetinib (for BRAF mutated melanoma). In addition to these newly added drug-based therapy options, the NCCN Guidelines® for Melanoma have also retained many other options for patients with advanced disease, including treatment in a clinical trial, pharmaceutical agents applied locally, regionally, or systemically, and other treatment modalities (e.g., surgery, radiation therapy, and laser ablation).  The recommended treatment options for advanced melanoma are diverse in mechanism of action, method of administration, safety profiles, and patterns of response.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Review recommended therapeutic options for treatment of advanced melanoma.
  • List the factors to consider and identify testing and experts needed to inform selection of therapy for advanced melanoma.
  • Identify the key players needed to assemble a clinical team with sufficient expertise to safely administer and accurately assess response for each of the treatments recommended for advanced melanoma.
Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.65 ANCC contact hours
  • 0.75 Participation
Course opens: 
11/18/2016
Course expires: 
11/18/2017
Cost:
$0.00

Gregory Daniels, MD, PhD
University of California, San Diego

Brian Hinds, MD
University of California, San Diego

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below has no relevant financial relationships to disclose:
Gregory Daniels, MD, PhD; Brian Hinds, MD

The activity planning staff listed below has no relevant financial relationships to disclose:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Anita Engh, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.65 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-118-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.65 ANCC contact hours
  • 0.75 Participation

Accreditation Period

Course opens: 
11/18/2016
Course expires: 
11/18/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing